These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 29530851)

  • 1. Inactivation of the Pseudomonas-Derived Cephalosporinase-3 (PDC-3) by Relebactam.
    Barnes MD; Bethel CR; Alsop J; Becka SA; Rutter JD; Papp-Wallace KM; Bonomo RA
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29530851
    [No Abstract]   [Full Text] [Related]  

  • 2.
    Karlowsky JA; Lob SH; Kazmierczak KM; Young K; Motyl MR; Sahm DF
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17.
    Lob SH; Karlowsky JA; Young K; Motyl MR; Hawser S; Kothari ND; Gueny ME; Sahm DF
    J Antimicrob Chemother; 2019 Aug; 74(8):2284-2288. PubMed ID: 31086960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro activity of imipenem/relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients - SMART Surveillance United States 2015-2017.
    Karlowsky JA; Lob SH; Kazmierczak KM; Young K; Motyl MR; Sahm DF
    Int J Antimicrob Agents; 2020 Jan; 55(1):105841. PubMed ID: 31704217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States - SMART 2015-2017.
    Karlowsky JA; Lob SH; Young K; Motyl MR; Sahm DF
    Diagn Microbiol Infect Dis; 2019 Oct; 95(2):212-215. PubMed ID: 31174995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme.
    Karlowsky JA; Lob SH; Kazmierczak KM; Hawser SP; Magnet S; Young K; Motyl MR; Sahm DF
    J Antimicrob Chemother; 2018 Jul; 73(7):1872-1879. PubMed ID: 29659861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City.
    Lapuebla A; Abdallah M; Olafisoye O; Cortes C; Urban C; Landman D; Quale J
    Antimicrob Agents Chemother; 2015 Aug; 59(8):5029-31. PubMed ID: 26014931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - Results from the SMART global surveillance program.
    Lob SH; Hackel MA; Kazmierczak KM; Hoban DJ; Young K; Motyl MR; Karlowsky JA; Sahm DF
    Diagn Microbiol Infect Dis; 2017 Jun; 88(2):171-176. PubMed ID: 28291628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae.
    Papp-Wallace KM; Barnes MD; Alsop J; Taracila MA; Bethel CR; Becka SA; van Duin D; Kreiswirth BN; Kaye KS; Bonomo RA
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29610205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections.
    Alonso-García I; Vázquez-Ucha JC; Lasarte-Monterrubio C; González-Mayo E; Lada-Salvador P; Vela-Fernández R; Aja-Macaya P; Guijarro-Sánchez P; Rumbo-Feal S; Muíño-Andrade M; Fernández-González A; Martínez-Guitián M; Beceiro A; Rodríguez-Iglesias M; Oliver A; Arca-Suárez J; Galán-Sánchez F; Bou G
    J Antimicrob Chemother; 2023 May; 78(5):1195-1200. PubMed ID: 36918743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa.
    Young K; Painter RE; Raghoobar SL; Hairston NN; Racine F; Wisniewski D; Balibar CJ; Villafania A; Zhang R; Sahm DF; Blizzard T; Murgolo N; Hammond ML; Motyl MR
    BMC Microbiol; 2019 Jul; 19(1):150. PubMed ID: 31272373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of imipenem-relebactam against various resistance phenotypes/genotypes of Enterobacterales and Pseudomonas aeruginosa isolated from patients across Canada as part of the CANWARD study, 2016-2019.
    Walkty A; Karlowsky JA; Baxter MR; Adam HJ; Golden A; Lagace-Wiens P; Zhanel GG;
    Diagn Microbiol Infect Dis; 2021 Sep; 101(1):115418. PubMed ID: 34102373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of imipenem/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015-2016.
    Karlowsky JA; Lob SH; Young K; Motyl MR; Sahm DF
    J Glob Antimicrob Resist; 2018 Dec; 15():140-147. PubMed ID: 30071354
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Lob SH; Hackel MA; Kazmierczak KM; Young K; Motyl MR; Karlowsky JA; Sahm DF
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of imipenem/relebactam plus aztreonam against metallo-β-lactamase-producing, OprD-deficient Pseudomonas aeruginosa with varying levels of Pseudomonas-derived cephalosporinase production.
    O'Donnell JN; Putra V; Belfiore GM; Maring BL; Young K; Lodise TP
    Int J Antimicrob Agents; 2022 Jun; 59(6):106595. PubMed ID: 35483625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of imipenem by relebactam for Pseudomonas aeruginosa from bacteraemia and respiratory infections.
    Horner C; Mushtaq S; Livermore DM;
    J Antimicrob Chemother; 2019 Jul; 74(7):1940-1944. PubMed ID: 31032858
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Lob SH; Karlowsky JA; Young K; Motyl MR; Hawser S; Kothari ND; Sahm DF
    J Med Microbiol; 2020 Feb; 69(2):207-217. PubMed ID: 31976856
    [No Abstract]   [Full Text] [Related]  

  • 19. Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants.
    Fraile-Ribot PA; Zamorano L; Orellana R; Del Barrio-Tofiño E; Sánchez-Diener I; Cortes-Lara S; López-Causapé C; Cabot G; Bou G; Martínez-Martínez L; Oliver A;
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31740559
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Asempa TE; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.